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Introduction 
 
The management of urticaria, although complex, relies 
on two postulates:  
 Recognition and eradication of the triggering 
factor(s)  
 Provision of symptomatic relief 
 
Recognition and eradication of the triggering 
factors(s) 
Factors known are drugs, food, infections, and 
physical stimuli. 
Drugs: Analgesics and NSAIDs can exacerbate already 
present urticaria and are also recognized triggers of 
new-onset urticaria.2 When suspected, they should be 
withdrawn entirely or can be replaced. ACE inhibitors 
can cause angioedema. 
Eradication of infectious agents  
Infections and infestations should be treated where 
suspected, including infections of the GI tract e.g., H 
Pylori associated gastritis3, nasopharyngeal bacterial 
infections and intestinal worms.8 
 
Management of diet 
The allergens in food need to be avoided if a patient 
has type I hypersensitivity to any one of these 
allergens. Pseudo-allergic reactions5 which are not IgE 
mediated have been described for organic foods and 
food additives.9-13 
Physical stimuli 
They are usually recognized and controlled, e.g., in 
chronic pressure urticaria patients are advised to use 
bags with a wide handle and similarly, in symptomatic 
dermographism, simple avoidance of friction can give 
relief from symptoms.15  
Symptomatic therapy 
One of the objectives of symptomatic therapy is to 
mask the effects of histamine, platelet-activating 
factor, and other mast cell mediators. Histamine plays 
a primary role in inducing the symptoms associated 
with urticaria. The activation of receptors on 
endothelial cells by histamine results in wheals 
whereas this histamine receptor activation on sensory 
nerves results in itching. Different guidelines have 
been proposed for managing chronic urticaria 
including the EACCI [5] and BSACI [4]. 
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Figure 1: Chronic Urticaria management algorithms.  
(A) European Academy of Allergy and Clinical Immunology/ Global Allergy and Asthma European Network/ 
European Dermatology Forum/ World Allergy Organization (EAACI/GA2LEN/EDF/WAO) guidelines 
(B) The US practice parameters for the diagnosis and management of chronic urticaria (CU).6  
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According to EACCI guidelines, the first choice in 
treating chronic urticaria is second-generation 
histamine type I receptor blockers.17 However, 
continuous treatment is recommended14 because of 
their non-sedating or minimally sedating properties 
free of anticholinergic side effects. More than four-fold 
higher doses can be used in the majority. Table 1 
enlists the commonly used H1 antihistamines in 
Pakistan. 
 
Table 1: Antihistamine (H1) commonly used for CU  
Drug Dose Class References 
Cetirizine 10 
mg 
Second-
generation 
antihistamine 
(22) 
Desloratadine 5 mg Second-
generation 
antihistamine 
(24) 
Fexofenadine 120-
180 
mg 
Second-
generation 
antihistamine 
 
(20) 
Levocetirizine 
 
5 mg Second-
generation 
antihistamine 
(25) 
Loratadine 
 
10 
mg 
Second-
generation 
antihistamine 
(27) 
Ebastine 10 
mg 
20 
mg 
Non-sedating 
antihistamine 
 
 
Safety data of H1 antihistamines are available 
regarding prolonged use.14 In the recent GA2LEN 
position paper15 first-generation antihistamines are no 
longer recommended. This view is shared by the 
World Allergy Organization guideline for Allergic 
Rhinitis and its Impact on Asthma.16 
Modern second-generation antihistamines17 
(loratadine, and fexofenadine) are non-sedating 
metabolites of earlier sedative antihistamines. 
Astemizole and terfenadine are disregarded because 
of cardiotoxic effects.15  
Seven of second-generation antihistamines (cetirizine, 
desloratadine, fexofenadine, levocetirizine, loratadine, 
rupatadine, and bilastine) have been tested in detail. 
Studies show the benefit of dose more than four-fold 
of the recommended dose.18,19 It has been verified 
using bilastine, cetirizine, desloratadine, levocetirizine, 
fexofenadine, and rupatadine.18,20 
H2-Antihistamines 
There is little evidence for their use.29 A combination of 
cimetidine with hydroxyzine results in increased 
hydroxyzine levels hence recommended only in 
hydroxyzine unresponsiveness. Cimetidine is not 
recommended in combination with cetirizine.30 The 
combination of ranitidine with terfenadine was 
superior to terfenadine alone in terms of itch, but not 
in wheals or swellings.31 
Treatment of refractory symptoms 
Repeated courses of glucocorticoids may be used33, but 
it may cause severe side effects without inducing 
remission or altering the course. So they are only 
advisable for short periods at the minimal effective 
dose while considering other options.  
 
Goal of Therapy 
 
There is no standardized approach.34 Options include 
omalizumab, and anti-inflammatory or 
immunosuppressants. Therapy must be 
individualized, considering concomitant medical 
conditions and patient preferences. 
 
Treatment strategies 
 
Any ineffective standard therapies should be 
discontinued. A baseline complete blood count and 
chemistry panel with liver function tests should be 
obtained prior to initiation.   
Drugs for refractory urticaria can be divided into three 
groups: 
1. Anti-inflammatory group 
Predominantly anti-inflammatory, with low toxicity 
and less proven efficacy e.g., dapsone, sulfasalazine, 
and hydroxychloroquine. 
2. Immunosuppressant group 
Potent immune suppression with greater toxicity and 
efficiency e.g; calcineurin inhibitors, sirolimus, and 
mycophenolate mofetil. 
3. Omalizumab 
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1. ANTI-INFLAMMATORY AGENTS: 
Table 2: Agents best studied in CU are dapsone, sulfasalazine, and hydroxychloroquine. 
Drug MOA Side Effects Dose 
Dapsone34  Sulfone 
Antimicrobial; 
Addition of dapsone 
to antihistamines 
showed earlier 
response than with 
antihistamines. 
Anemia, neuropathy, 
hepatotoxicity, 
methaemoglobinaemia, 
DRESS syndrome. 
100mg. 
Sulfasalazine35 5-Aminosalicylic 
Acid derivative. 
Nausea, gastrointestinal 
discomfort, mild headache, 
leucopenia, and elevated liver 
function tests. 
Start with 500 mg 
daily, increase by 
500 mg per week to 
2000 mg daily. 
Hydroxychloroquine34 Anti-inflammatory; 
Anti-malarial; 
Suppression of T-cell 
activation; 
Disruption of 
antigen processing 
of macrophages 
Slow onset of action. Adults: 200 mg 
twice daily. 3 
months’ trial 
required. 
 
 
 
2. IMMUNOSUPPRESSIVE AGENTS: 
Table 3: Immunosuppressant Agents. 
Drug  MOA Side Effects  Dose 
1-Calcineurin Inhibitors 38, 39, 40 
 
Cyclosporine41 
(Rapid onset,  
Lasting remission) 
 
 
Inhibit the calcium-
dependent release of 
histamine, leukotriene 
C4 and mediators in 
mast cells. Has anti-T 
lymphocyte activity; 
May disrupt TNF-alpha 
activity. 
 3 -5 mg per kg daily, tapering 
after remission.43 
Tacrolimus44 Same as cyclosporine.  1mg twice daily for 1 week; 
increased to 2mg twice daily. 
2-Sirolimus 
(Rapamycin)45 
The substrate of 
cytochrome P450 3A4. 
Headache, arthralgias, 
rash, 
dyslipoproteinaemia 
cytopenias, and immune 
suppression-related 
neoplasia or infections. 
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3. OMALIZUMAB: 
This recombinant humanized monoclonal IgG 
antibody binds free IgE, down-regulates mast cell 
function and induces eosinophil apoptosis25 through 
the reduction of FcεRI in basophils and mast cells.47 It 
has proven efficacy in refractory CU. Add-on therapy 
with subcutaneous omalizumab 300 mg every 4 weeks 
for 12 or 24 weeks, reduced itching severity, hives, and 
angioedema. It is the second choice in the EAACI 
guidelines6 and officially approved by the European 
Regulatory Agency.25 Efficacy is proven in 
symptomatic dermographism, cold urticaria, heat 
urticaria, delayed pressure, solar and cholinergic 
urticaria.48 
Dosing — Two doses approved by the FDA are 150 
mg or 300 mg every four weeks. If the response is 
adequate, taper to a lower dose (e.g., 150 mg every 
four or six weeks). An algorithm for dose 
individualization has been proposed. Treated patients, 
who, after stopping therapy, had a recurrence, have 
been reported to respond to omalizumab again, 
suggesting that resistance does not develop readily. 
Monitoring — No specific laboratory monitoring is 
required for patients receiving omalizumab. 
Side Effects   There appears to be no reported side 
effect. However, transient hair loss was reported in 
three subjects who continued therapy despite it.49 
 
Therapies with Significant 
Limitations 
 
Some additional agents that can be useful, albeit with 
limitations. Glucocorticoids remain the standard 
comparator.  
Immunoglobulin   
Used where immunomodulation is preferable to 
immunosuppression, e.g., history of malignancy. It 
alters cell adhesion, immunoregulatory molecules, 
complement function, cytokine levels, and 
autoantibody production.50 It can be administered 
intravenously [IVIG]) or subcutaneously [SCIG]. 
Adverse effects are generally predictable and 
manageable. It may be dosed individually, the optimal 
dose, number of infusions and schedule are unknown. 
TNF-inhibitors 
Tumor necrosis factor (TNF)-alpha is upregulated in 
the epidermis in lesional and nonlesional skin. 
Etanercept, adalimumab, and infliximab have been 
studied.51 However, the effectiveness is limited. 
Colchicine  
It acts by suppressing leukotriene generation or 
leukocyte adhesiveness and migration.2 It is safe at 
recommended doses, with a rapid onset of action. 
Androgens  
These are effective in hereditary angioedema and have 
been studied in chronic idiopathic urticaria and 
angioedema.52 
Methotrexate 
It reduces neutrophil accumulation2, diminishes 
leukocyte adhesiveness, leukotriene synthesis, and 
alters cytokine activity.53 Efficacy is limited.54 Doses 
ranged from 5-25 mg/week and effects observed after 
four weeks. 
Cyclophosphamide  
Reserved where multiple alternative agents have 
failed.22 It is believed to act on plasma cells to reduce 
autoantibody production in autoimmune CU.  
Antifibrinolytics 
These55 are useful because coagulation and 
inflammatory pathways in urticaria are 
interconnected.22 Serine protease inhibitors decrease 
proteases including tryptase, kallikrein, complement, 
factor XII, and plasmin e.g., tranexamic acid 
Methylxanthines  
Theophylline.56  
I/M or aerosolized epinephrine (BASCI): 
Intramuscular epinephrine not routinely prescribed 
except for self-administration in angioedema affecting 
the upper airway.  
 
Nondrug therapies  
Nondrug treatments that have been studied in CU 
include phototherapy, autohemotherapy, and 
plasmapheresis. 
Phototherapy 
It is useful in solar and physical urticarias, suitable for 
patients who visit frequently or intolerant to systemic 
treatment.57 Narrowband UVB is effective, safe and 
affordable for steroid-dependent CRU.    
Autohemotherapy 
It58 involves the parenteral injection of autologous 
blood to desensitize patients to pro-urticarial factors in 
his serum2 and improved quality of life.3 
Plasmapheresis 
It removes proteins and other substances and may be 
immunomodulatory.59 However, it is not easily 
available and not recommended for routine use.  
Inducing Tolerance 
It can be useful in physical, cholinergic, solar and cold 
urticarias. However, it lasts only a few days. A 
consistent exposure is required, which is often not 
acceptable.15 
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Table 4:  Recommendations for treatment of chronic 
urticaria: Representative sampling of clinical 
guidelines and expert panel opinions. 
Ref Recommendations 
EAACI/GA
2LEN/EDF
/WAO 
guideline  
Second-generation histamine type I 
receptor blockers should be the first 
choice for symptomatic relief. 
Sedating antihistamines should not be 
used for routine management as first-
line agents 
BSACI 
guidelines  
Non-sedating H1-antihistamines are 
the mainstay of therapy. Chronic use 
of these should be discouraged as it 
can lead to psychomotor dysfunction 
and heavy sedation 
AAITO 
position 
paper  
Low-sedating H1-antihistamines as 
first-line therapy 
Sedating H1-antihistamines if the 
patient is anxious and disturbed at 
night 
SFD 
Consensus 
Conference 
Recommend
ations  
Monotherapy with a second-
generation H1-antihistamine is the 
preferred treatment. This drug 
controls the disease in the majority.  
Joint Task 
Force on 
Practice 
Parameters  
 
Symptomatic treatment with H1-
antihistamines remains the mainstay 
of management; Sedation does not 
occur at recommended doses except 
for cetirizine. Sedation may reduce 
the discomfort of pruritus, but may 
cause undesirable and potentially 
dangerous side effects 
BAD 
therapy 
guidelines  
Histamine type I receptor blockers 
which do not cause significant 
sedation are the mainstay of 
treatment. As the response and 
tolerance may vary among patients, 
the choice of a minimum of two non-
sedating antihistamines should be 
offered to them.  
Khan 2008  Second-generation of histamine type I 
receptor blockers should be the first 
choice 
Muller 2004  2nd generation H1-receptor 
antagonists should be used as first-
line treatment 
Kaplan 2002  There is general agreement that non-
sedating antihistamines are the first 
choice for treatment 
 
 
Special Populations 
 
Children: A significant proportion of children (50 – 
80%) with chronic urticaria have concomitant 
angioedema. [BASCI} Cold and pressure are the most 
frequent precipitating factors. 4% have anti-thyroid 
antibodies. A detailed clinical history along with 
examination is needed. Allergy tests can be employed 
to diagnose the type I hypersensitivity reaction (IgE 
mediated allergies). An elimination and re-challenge 
diets may be required in some cases.   
Chronic urticaria and angioedema management in 
children 
The initial treatment depends on the severity of 
disease manifestation. The therapy is highly 
individualized, it is tailored and tapered according to 
the response of the patient. High dose steroid therapy 
(up to 40 mg/ day) may be used for three days in case 
of severe exacerbations. Once the disease is under 
control the dose can be tapered. Latest Evidence on the 
mode of antihistamine action51 suggests that it is better 
to tapper and stop than to stop such therapy suddenly. 
Histamine receptor blockers are the backbone of 
management. 2nd generation drugs are preferred and 
may be given in combination with sedating first-
generation in case of unresponsiveness. However, 
these are not recommended for use in children <6 
months of age. Cetirizine and loratadine are licensed 
for use in 2 years and older and desloratadine to 1 year 
and older. 1st generation antihistamines that cause 
considerable sedation, can be used in childhood. These 
drugs include diphenhydramine, hydroxyzine, 
promethazine, and chlorphenamine. Among all these, 
only chlorphenamine and hydroxyzine are 
recommended for use in children under 2 years. 
Corticosteroids are recommended in the resistance of 
the maximal dose of H1 antihistamines with the 
addition of H2 blockers and leukotrienes. More 
effective in delayed-pressure urticarias, but side-
effects should be monitored.  
Pregnancy: Most of the antihistamines are not 
contraindicated in pregnancy and can be used safely. 
Loratadine & hydroxyzine have shown teratogenicity 
at high doses in animals. Chlorpheniramine, loratadine 
& cetirizine have been recommended as Class B drugs 
in pregnancy. However, the lowest possible doses 
should be used.  
Breastfeeding: Antihistamines are only recommended 
for breast-feeding if potential benefits outweigh the 
risk as the majority of the drugs are excreted in the 
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human breast milk. Chlorpheniramine can cause 
drowsiness and poor feeding.  
 
Conclusion 
  
Urticaria significantly affects the quality of life and 
therefore its early and effective treatment is 
imperative. Sound cooperation between the patient 
and the treating physician is required for successful 
therapy. The objective is to make the patient 
asymptomatic and hence elevate his quality of life. An 
individualized approach is required and the treatment 
of chronic urticaria needs to be tailored differently for 
each patient because of the highly variable disease 
presentation.  
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